

NEWS RELEASE

HYDERABAD, INDIA (6 Nov' 2021) - SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced unaudited financial results for the quarter and half-year ended 30 Sept' 2021. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 6 Nov' 2021 at Hyderabad.

Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Period ended	
	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20
Revenue	3,393.23	2,695.84	2,377.45	6,089.08	4,817.16
EBITDA	1,601.10	1,203.99	982.30	2,805.10	2,155.91
EBITDA Margin	47.19%	44.66%	41.32%	46.07%	44.75%
EBIT	1,509.33	1,114.06	907.30	2,623.39	2,010.27
EBIT Margin	44.48%	41.33%	38.16%	43.08%	41.73%
Finance costs	11.75	21.26	26.43	33.01	53.63
Depreciation	91.77	89.93	75.00	181.70	145.64
Taxes	345.60	278.39	227.57	624.00	491.04
Taxes to PBT	23.08%	25.48%	25.83%	24.09%	25.10%
PAT (Standalone) #	1,151.98	814.41	653.30	1,966.39	1,465.60
PAT Margin (Standalone)	33.95%	30.21%	27.48%	32.29%	30.42%
Associate Company	174.63	236.49	87.53	411.12	190.70
PAT (Consolidated)	969.85	1,050.83	740.79	2,020.68	1,656.01
PAT Margin (Consolidated)	28.58%	38.98%	31.16%	33.19%	34.38%
EPS (Standalone)	4.53	3.20	2.57	7.72	5.76
EPS (Consolidated)	3.81	4.13	2.91	7.94	6.51
Paid up share capital (Re.1/sh)	254.56	254.57	254.57	254.56	254.57

PAT (Standalone) include INR 332.94 Mn, Dividend from Suven Pharma, Inc., USA

Growth Ratios

	Quarter ended 30 Sep 21 to Quarter ended 30 Jun 21	Quarter ended 30 Sep 21 to Quarter ended 30 Sep 20	Period ended 30 Sep 21 to Period ended 30 Sep 20
Growth in income	25.87%	42.73%	26.40%
Growth in EBITDA	32.98%	62.99%	30.11%
Growth in EBIT	35.48%	66.35%	30.50%
Growth in PAT Standalone	41.45%	76.33%	34.17%
Growth in PAT Consolidated	-7.71%	30.92%	22.02%

1. The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
2. The consolidated financials include the results of the wholly owned subsidiary Suven Pharma, Inc., and associate Rising Pharma Holdings, Inc., USA.
3. The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA.

Suven Pharmaceuticals Limited

4. Apart from the above, the shortage or non-availability of vessels leading to delay in shipments, increase in the transportation and distribution costs and timely non availability of materials with increase in materials cost are impacting our operations and profitability.

For more information, please visit: <http://www.suvenpharm.com>

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited